[{"orgOrder":0,"company":"TaiRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Foslinanib","moa":"angiogenesis inhibitors; phosphoro-derivatives","graph1":"Oncology","graph2":"Phase II","graph3":"TaiRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TaiRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TaiRx \/ Undisclosed"},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"TaiRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"Foslinanib","moa":"||angiogenesis inhibitors; phosphoro-derivatives","graph1":"Oncology","graph2":"Phase II","graph3":"Bora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bora Pharmaceuticals \/ TaiRx","highestDevelopmentStatusID":"8","companyTruncated":"Bora Pharmaceuticals \/ TaiRx"},{"orgOrder":0,"company":"Golden Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Antroquinonol","moa":"DNA [cytosine-5]-methyltransferase 1 (DNMT1)","graph1":"Oncology","graph2":"Phase II","graph3":"Golden Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Golden Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Golden Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Golden Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Antroquinonol","moa":"DNA [cytosine-5]-methyltransferase 1 (DNMT1)","graph1":"Oncology","graph2":"Phase II","graph3":"Golden Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Golden Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Golden Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Golden Biotechnology","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Antroquinonol","moa":"DNA [cytosine-5]-methyltransferase 1 (DNMT1)","graph1":"Oncology","graph2":"Phase II","graph3":"Golden Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Golden Biotechnology \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Golden Biotechnology \/ Icon Plc"},{"orgOrder":0,"company":"Golden Biotechnology","sponsor":"PharmaNet","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Antroquinonol","moa":"DNA [cytosine-5]-methyltransferase 1 (DNMT1)","graph1":"Oncology","graph2":"Phase II","graph3":"Golden Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Golden Biotechnology \/ PharmaNet","highestDevelopmentStatusID":"8","companyTruncated":"Golden Biotechnology \/ PharmaNet"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lipotecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Taiwan Liposome Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiwan Liposome Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Taiwan Liposome Company \/ Undisclosed"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lipotecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Taiwan Liposome Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiwan Liposome Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Taiwan Liposome Company \/ Undisclosed"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Lipotecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Taiwan Liposome Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiwan Liposome Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Taiwan Liposome Company \/ Undisclosed"},{"orgOrder":0,"company":"TTY BIOPHARM CO LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase II","graph3":"TTY BIOPHARM CO LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TTY BIOPHARM CO LTD \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TTY BIOPHARM CO LTD \/ Undisclosed"},{"orgOrder":0,"company":"TTY BIOPHARM CO LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase II","graph3":"TTY BIOPHARM CO LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TTY BIOPHARM CO LTD \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TTY BIOPHARM CO LTD \/ Undisclosed"},{"orgOrder":0,"company":"GNT Biotech & Medicals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Chidamide","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase II","graph3":"GNT Biotech & Medicals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GNT Biotech & Medicals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GNT Biotech & Medicals \/ Undisclosed"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"OBI-833","moa":"Globo H","graph1":"Oncology","graph2":"Phase II","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"OBI Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OBI Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"OBI-833","moa":"Globo H","graph1":"Oncology","graph2":"Phase II","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"OBI Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OBI Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Anbogen Therapeutics","sponsor":"KGI Venture Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2024","type":"Series A Financing","leadProduct":"ABT-301","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Anbogen Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Anbogen Therapeutics \/ KGI Venture Capital","highestDevelopmentStatusID":"8","companyTruncated":"Anbogen Therapeutics \/ KGI Venture Capital"},{"orgOrder":0,"company":"Anbogen Therapeutics","sponsor":"BeOne Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"ABT-301","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Anbogen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anbogen Therapeutics \/ BeiGene","highestDevelopmentStatusID":"8","companyTruncated":"Anbogen Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"OPT-822","moa":"Hemocyanin 1 | Globohexaosylceramide","graph1":"Oncology","graph2":"Phase II","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OBI Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OBI Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merdury Pharmaceutical","sponsor":"Ainos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Protein","year":"2023","type":"Agreement","leadProduct":"Interferon Alpha","moa":"IFNAR","graph1":"Oncology","graph2":"Phase II","graph3":"Merdury Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Merdury Pharmaceutical \/ Ainos","highestDevelopmentStatusID":"8","companyTruncated":"Merdury Pharmaceutical \/ Ainos"},{"orgOrder":0,"company":"TTY BIOPHARM CO LTD","sponsor":"Chang Gung Memorial Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Megestrol Acetate","moa":"Progesterone receptor","graph1":"Oncology","graph2":"Phase II","graph3":"TTY BIOPHARM CO LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TTY BIOPHARM CO LTD \/ Chang Gung Memorial Hospital","highestDevelopmentStatusID":"8","companyTruncated":"TTY BIOPHARM CO LTD \/ Chang Gung Memorial Hospital"},{"orgOrder":0,"company":"TaiRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"TaiRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TaiRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TaiRx \/ Undisclosed"},{"orgOrder":0,"company":"Holy Stone Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CA102N","moa":"Prostaglandin G\/H synthase 2 (COX-2)","graph1":"Oncology","graph2":"Phase II","graph3":"Holy Stone Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Holy Stone Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Holy Stone Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Holy Stone Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CA102N","moa":"Prostaglandin G\/H synthase 2 (COX-2)","graph1":"Oncology","graph2":"Phase II","graph3":"Holy Stone Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Holy Stone Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Holy Stone Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Primo Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Radiolabeled Compound","year":"2025","type":"Series A Financing","leadProduct":"PB011","moa":"PSMA","graph1":"Oncology","graph2":"Phase II","graph3":"Primo Biotechnology","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Primo Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Primo Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"TTY BIOPHARM CO LTD","sponsor":"National Cheng-Kung University Hospital | National Taiwan University Hospital | Taipei Veterans General Hospital | Chang Gung Memorial Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"TTY BIOPHARM CO LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TTY BIOPHARM CO LTD \/ National Cheng-Kung University Hospital | National Taiwan University Hospital | Taipei Veterans General Hospital | Chang Gung Memorial Hospital","highestDevelopmentStatusID":"8","companyTruncated":"TTY BIOPHARM CO LTD \/ National Cheng-Kung University Hospital | National Taiwan University Hospital | Taipei Veterans General Hospital | Chang Gung Memorial Hospital"},{"orgOrder":0,"company":"TTY BIOPHARM CO LTD","sponsor":"Chang Gung Memorial Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"TTY BIOPHARM CO LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TTY BIOPHARM CO LTD \/ Chang Gung Memorial Hospital","highestDevelopmentStatusID":"8","companyTruncated":"TTY BIOPHARM CO LTD \/ Chang Gung Memorial Hospital"},{"orgOrder":0,"company":"TTY BIOPHARM CO LTD","sponsor":"Taipei Veterans General Hospital | National Taiwan University Hospital | Chang Gung Memorial Hospital | National Cheng-Kung University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"TTY BIOPHARM CO LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TTY BIOPHARM CO LTD \/ Taipei Veterans General Hospital | National Taiwan University Hospital | Chang Gung Memorial Hospital | National Cheng-Kung University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"TTY BIOPHARM CO LTD \/ Taipei Veterans General Hospital | National Taiwan University Hospital | Chang Gung Memorial Hospital | National Cheng-Kung University Hospital"},{"orgOrder":0,"company":"TaiRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Sorafenib","moa":"Serine\/threonine-protein kinase RAF","graph1":"Oncology","graph2":"Phase II","graph3":"TaiRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TaiRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TaiRx \/ Undisclosed"},{"orgOrder":0,"company":"Lukas Biomedical","sponsor":"Virginia Contract Research Organization","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Activated T Lymphocyte","moa":"T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Lukas Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lukas Biomedical \/ Virginia Contract Research Organization","highestDevelopmentStatusID":"8","companyTruncated":"Lukas Biomedical \/ Virginia Contract Research Organization"},{"orgOrder":0,"company":"Pharmadax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"99m-Tc H7ND","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Pharmadax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pharmadax \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pharmadax \/ Undisclosed"},{"orgOrder":0,"company":"Pharmadax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"99m-Tc H7ND","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Pharmadax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmadax \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pharmadax \/ Undisclosed"},{"orgOrder":0,"company":"Microbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"MB-6","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Microbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Microbio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Microbio \/ Undisclosed"},{"orgOrder":0,"company":"SynCore Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"SCB01A","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"SynCore Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SynCore Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SynCore Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"SynCore Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"SCB01A","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"SynCore Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SynCore Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SynCore Biotechnology \/ Undisclosed"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
